PCI Pharma Services expands Berlin cold chain clinical supply storage capabilities
![](/46/pdcnewsitem/11/13/08/HLN00CPO_Cold_chain_990x525.jpg)
The move ensures the service provider has the capacity to meet the needs of an evolving clinical market
PCI Pharma Services says it has expanded its cold chain clinical supply storage and distribution capabilities at its Berlin location in a bid to provide global access to regional customers.
The company has added capacity and several new cold chain storage conditions to its capabilities, which now include temperatures from controlled room temperature to -80 °C.
The pharmaceutical packaging and services provider has doubled the size of its 2–8 °C storage and added -20 °C and -80 °C. In phase two of the expansion, set to begin in FY 2022, PCI plans to add liquid nitrogen storage capabilities at the Berlin site.
The Berlin facility, which is dedicated to secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution, recently passed mandatory regulatory inspection for these expansions, and it is now fully operational.
PCI said the Berlin facility is now congruent with all its global facilities, helping the company to support the vaccine supply chain and keep pace with growing demands for biologic therapies.
It said the added capacity is well positioned to service small-to-medium sized pharmaceutical companies within mainland Europe (EU), which are conducting clinical trials in the EU, as well as in North America and other parts of the world.
The expansion is the latest in a series of global clinical expansions the company has made across multiple continents and four other sites, including San Diego; Rockford, Illinois; Bridgend, UK; and Australia.
In July 2020, PCI completed a new Clinical Center of Excellence in Berlin following the acquisition of Bellwyck Pharma Services in early 2020.
With the Berlin and Bridgend locations, PCI now services both mainland Europe and mainland UK, which the company said remains an important focus post-Brexit.
![PCI Pharma Services](https://www.cphi-online.com/th248330-comp248330.png)
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance